Information Provided By: 
Fly News Breaks for June 19, 2019
AIMT
Jun 19, 2019 | 05:14 EDT
Following a dinner with management which included a review of the Phase 3 Artemis data, Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Aimmune Therapeutics with a $60 price target. The key takeaway from the event was the continued execution by management to successfully position AR101 for approval, Raymond tells investors in a research note. The analyst continues to see the setup on Aimmune as "decidedly positive" and he remains a buyer of the stock.
News For AIMT From the Last 2 Days
There are no results for your query AIMT
